Related Experiment Video

Updated: May 22, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients

Ching-Yi Lee1,2,3, Shih-Wei Lee1,3, Yi-Chiung Hsu2,4,5

  • 1Department of Internal Medicine, Tao Yuan General Hospital, Taoyuan 33004, Taiwan.

International Journal of Molecular Sciences
|March 13, 2025
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) revolutionized EGFR-mutant non-small cell lung cancer (NSCLC) treatment, but resistance emerges. This study explores resistance mechanisms and future strategies for advanced lung cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Tyrosine kinase inhibitors (TKIs) transformed treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
  • Acquired drug resistance to first-line TKIs is a significant clinical challenge, necessitating evolving treatment guidelines.
  • Understanding resistance mechanisms is crucial for developing effective sequential therapies.

Purpose of the Study:

  • To review potential mechanisms of drug resistance to first-line TKI therapy in EGFR-mutant NSCLC.
  • To discuss emerging and potential successive treatment strategies for managing TKI resistance.
  • To propose future directions for treatment and resistance management in advanced NSCLC.

Main Methods:

  • Literature review of TKI resistance mechanisms in EGFR-mutant NSCLC.
  • Analysis of current and emerging combination treatment regimens.
  • Discussion of the role of next-generation sequencing (NGS) in evaluating resistance.

Main Results:

  • Drug resistance to first-line TKIs is a common clinical issue in EGFR-mutant NSCLC.
  • Next-generation sequencing (NGS) aids in identifying resistance mechanisms.
  • Combination therapies and novel agents show promise in overcoming resistance.

Conclusions:

  • Sequential treatment strategies are essential for managing acquired resistance to TKIs in EGFR-mutant NSCLC.
  • Ongoing clinical trials are exploring new therapeutic combinations and agents.
  • Personalized treatment approaches guided by molecular profiling are key for future management.
Keywords:
epidermal growth factor receptor (EGFR)next-generation sequencing (NGS)non-small cell lung cancer (NSCLC)tyrosine kinase inhibitors (TKIs)

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K